MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
LENSAR Accounts Receivables 2011-2026 | LNSR
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables LENSAR
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.38 M | 6.08 M | 4 M | 6.04 M | 4.64 M | 2.01 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.38 M | 2.01 M | 4.86 M |
Quarterly Accounts Receivables LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | 4.99 M | 6.88 M | 6.08 M | 4.37 M | 5.89 M | - | 4 M | 3.85 M | 3.22 M | 4.66 M | 6.04 M | 3.56 M | 2.76 M | 3.58 M | 4.64 M | 2.8 M | 2.7 M | 2.1 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 3.38 M | 3.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.88 M | 2.01 M | 3.87 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 13.17 | 0.46 % | $ 1.78 B |  USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 10.8 | 4.05 % | $ 387 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
24.7 M | $ 25.6 | -0.43 % | $ 216 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.47 | 4.52 % | $ 130 M |  France |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.12 | 3.92 % | $ 1.29 M | USA |
 |
Inspire Medical Systems
INSP
|
120 M | $ 56.7 | 1.0 % | $ 1.67 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 61.0 | 1.5 % | $ 3.33 B |  Britain |
 |
ClearPoint Neuro
CLPT
|
6.55 M | $ 11.37 | 1.7 % | $ 322 M | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.61 | 0.36 % | $ 38 M | USA |
 |
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | USA |
 |
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.65 | 3.92 % | $ 367 M | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 5.4 | 12.97 % | $ 1.14 B | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
178 K | $ 2.41 | 14.22 % | $ 6.68 M | USA |
 |
Globus Medical
GMED
|
679 M | $ 91.34 | 1.29 % | $ 12.4 B | USA |
 |
TransMedics Group
TMDX
|
84.3 M | $ 100.01 | -0.77 % | $ 3.4 B | USA |
 |
NanoVibronix
NAOV
|
289 K | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 36.8 | 0.38 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
346 M | $ 84.03 | -5.06 % | $ 2.92 B | USA |
 |
Stryker Corporation
SYK
|
4.04 B | $ 294.73 | -6.47 % | $ 113 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
660 M | $ 83.98 | 0.57 % | $ 49.1 B | USA |
 |
Tandem Diabetes Care
TNDM
|
165 M | $ 19.41 | -0.61 % | $ 1.32 B | USA |
 |
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.35 | 5.47 % | $ 54.9 M | USA |
 |
MiMedx Group
MDXG
|
75.7 M | $ 3.68 | 9.52 % | $ 544 M | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.9 | 4.16 % | $ 37.7 M | USA |